Role of STAT3 signaling pathway in breast cancer.

Ma JH, Qin L, Li X. · 2020

Read Role of STAT3 signaling pathway in breast cancer. by Ma JH, Qin L, Li X. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7048131.txt.

Introduction

Ma, Qin, and Li review the STAT3 signalling pathway in breast cancer for Cell Communication and Signaling. Breast cancer is the second leading cause of cancer death in women, and drug resistance limits the few treatments available. STAT3, a transcription factor, serves as an early tumour marker. When overactive and switched on constantly, it promotes malignancy.

Clinical and laboratory evidence ties active STAT3 to tumour growth, spread, and resistance to chemotherapy. New work has mapped regulators above STAT3 and target genes below it, filling in the pathway's wiring. Small molecule inhibitors that block STAT3 activation show promise as treatments. The review gathers these advances systematically, from pathway discovery to drug candidates. Its message is practical: a single overactive switch helps drive this cancer, and learning to turn it off could give resistant tumours a new line of attack.

Catalog record

CREATORMa JH, Qin L, Li X.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE56 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7048131

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Role of STAT3 signaling pathway in breast cancer By Jia-hui Ma, Li Qin, Xia Li Published in: Cell Communication and Signaling : CCS DOI: 10.1186/s12964-020-0527-z ABSTRACT Abstract Breast cancer has grown to be the second leading cause of cancer-related deaths in women. Only a few treatment options are available for breast cancer due to the widespread occurrence of chemoresistance, which emphasizes the need to discover and develop new methods to treat this disease. Signal transducer and activator of transcription 3 (STAT3) is an early tumor diagnostic marker and is known to promote breast cancer malignancy. Recent clinical and preclinical data indicate the involvement of overexpressed and constitutively activated STAT3 in the progression, proliferation, metastasis and chemoresistance of breast cancer. Moreover, new pathways comprised of upstream regulators and downstream targets of STAT3 have been discovered. In addition, small molecule inhibitors targeting STAT3 activation have been found to be efficient for therapeutic treatment of breast cancer. This systematic review discusses the advances in the discovery of the STAT3 pathways and drugs targeting STAT3 in breast cancer. [Figure: Video abstract] Keywords: STAT3, Breast cancer, Oncogene, Small molecule inhibitors BACKGROUND Transcription factors (TFs) are proteins possessing domains that bind to the DNA of promoter or enhancer regions of specific genes. Several TFs are directly involved in the development and progression of breast cancer. One of the most prominent TF families in breast cancer is the signal transducers and activators of transcription (STAT) family, which is comprised of seven structurally similar and highly conserved members, namely, STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6 [1, 2]. In general, these family members contain six common functional domains: an N-terminal domain (NH2) which is called STAT_int now, a coiled-coil domain (CCD), a DNA-binding domain (DBD), a linker domain, an SRC homology 2 domain (SH2) and a transactivation domain (TAD) [3]. Since the discovery of STAT3 in 1994, research has been primarily focused on its close association with cancer progression, proliferation, metastasis and multidrug resistance [4, 5]. Extensive reviews have described the classical STAT3 signaling pathways [6–8]. Here, we present a short overview of the STAT3 signaling pathways as depicted in Fig. 1. Briefly, STAT3 is activated through several cytokines, including interleukin 6 (IL-6) and interleukin 10 (IL-10), and growth factors, including epidermal growth factor (EGF), fibroblast growth factor (FGF) and insulin-like growth factor (IGF) [9, 10]. Once these factors bind to their corresponding receptors, Janus kinases (JAKs) are activated [11]. JAKs phosphorylate the cytoplasmic tail of the cognate receptor and STAT3 via its SH2 domain binds to phosphorylated tyrosine residues. The phosphorylated STAT3 forms homodimers and translocate into nucleus and, thus, can exchange signals between the cytoplasm and nucleus. Upon translocation into the nucleus, pSTAT3 forms a complex with some coactivators, including p68, and binds to the promotor region of target genes to activate their transcription [12]. This review aims to explore the mechanism of STAT3 in breast cancer development and summarize the latest advancements made. [Figure: The classical IL-6/STAT3 signaling pathway in cancer cells. IL-6 binds to the membrane-bound IL-6 receptor α (IL-6R) and IL-6 receptor β (also known as gp130). The IL-6/IL-6R/gp130 complex activate the phosphorylation of JAKs, followed by STAT3 phosphorylation and activation. Growth factors, such as FGF, IGF and EGF, can also phosphorylate STAT3 by binding to their cognate membrane receptors. Then, phosphorylated STAT3 forms a homodimer and translocates into the nucleus to bind to the promotor region of target genes and activates target gene transcription] ADVANCES IN THE STUDY OF STAT3 SIGNALING PATHWAYS IN BREAST CANCER The role of STAT3 in breast cancer progression An illustration of the advances in our understanding of the STAT3 signaling pathways in breast cancer progression is shown in Fig. 2. A member of the IL-6 family of cytokines, Oncostatin M (OSM) can induce IL-6 upregulation and STAT3 phosphorylation to promote breast cancer progression [13] and to activate STAT3 and hypoxia inducible factor 1 alpha (HIF-1α) in estrogen receptor (ER)- breast cancer cells or in ER+ breast cancer cells in cooperation with IL-6 [14]. Additionally, other interleukins, such as IL-35 and IL-8, are also found to promote breast cancer progression by activating STAT3. IL-35 is found to inhibit conventional T (T-conv) cells and promote breast cancer progression via activation of STAT1 and STAT3 [15], whereas IL-8 and growth-regulated oncogene (GRO) chemokines are found to activate STAT3 and promote the progression of inflammatory breast cancer [16]. In contrast, low expression of IL-17 is found to inhibit STAT3 activation [17]. [Figure: Advances of the STAT3 signaling pathways involved in breast cancer progression. Interleukins, including IL-6, IL-8 and IL-35, can bind to their receptors and activate the phosphorylation of JAKs and STAT3, OSM can increase IL-6-mediated activation, and IL-17 binding to its receptor leads to inhibition of STAT3 phosphorylation. STAT3 phosphorylated by EGF can be inhibited by PTPN2. COX2 and prostaglandin E2 upregulated by HDAC6 can activate STAT3 phosphorylation, and SMYD2 has a similar effect. Additionally, STAT3 and NEAT1 can form a loop to activate the phosphorylation of STAT3, which is inhibited by miR-124. The activated and phosphorylated STAT3 dimers translocate into the nucleus and activate the transcription of target genes involved in breast cancer progression] Other mediators of STAT3 expression and activation include activators, such as prostaglandin E2, cyclooxygenase-2 (COX2) and SET and MYND (myeloid-Nervy-DEAF-1) domain-containing protein (SMYD2), as well as its inhibitors, such as microRNA and protein tyrosine phosphatase 2 (PTPN2). Epigenetic regulators have been widely investigated and discovered to regulate STAT3 activation in breast cancers in recent years. Li et al. have found that histone deacetylase 6 (HDAC6), a class II histone deacetylase, and prostaglandin E2 and COX2, can upregulate STAT3 activation in breast cancer [18]. In addition, lysine methyltransferase SMYD2 can activate the methylation and phosphorylation of STAT3 to promote breast cancer progression [19]. MicroRNA (miR) has become a hot topic in the fields of cancer biology and development in recent years. Pang et al. have demonstrated that nuclear enriched abundant transcript 1 (NEAT1) forms a feedback loop with STAT3 to promote breast cancer progression. However, NEAT1 is suppressed by miR-124 [20]. Interestingly, glucosamine is found to suppress the activation of STAT3 and decrease breast cancer stemness and progression [21]. Additionally, knockdown of PTPN2 leads to EGF-mediated STAT3 activation [22]. The association of chronic inflammation with breast cancer progression is widely recognized, but it can be inhibited by blocking STAT3 [23]. Other mediators of STAT3 signaling pathways are also extensively studied. Kim et al. have found that the IL-6/STAT3/ROS pathway can not only promote breast cancer progression and inflammation but also increase the formation of breast cancer stem cells [24]. Moreover, TGFβ-regulated FAM3C/Interleukin-like EMT Inducer (ILEI), an oncogenic member of the FAM3 cytokine family, can mediate STAT3 signaling pathway to drive breast cancer stem cell formation and promote breast cancer progression [25]. In addition, TNFRSF1A, a gene encoding a transmembrane receptor for TNF-α, can be modulated by STAT3 and promote NF-κB signaling in breast cancer [26]. There were also some STAT3 co-factors influenced the proliferation and progress of breast cancer. Progranulin (PGRN), was seen to associate with chemoresistance and worse prognosis in breast cancer [27, 28], and the use of a specific progranulin antisense oligonucleotide was recently seen to hamper STAT3 oncogenic functions in CRC cells

Read the complete text